COMMUNIQUÉS West-GlobeNewswire

GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2017

09/01/2018 - 13:05

CARLSBAD, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK ), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and [...]

Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis

09/01/2018 - 13:05

PETALUMA, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the [...]

Summit Therapeutics to Present at the Biotech Showcase

09/01/2018 - 13:01

Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE Oxford, UK, 9 January 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and [...]

Medtronic Enrolls First Patient In Pain Study to Assess Optimized Spinal Cord Stimulation Programming

09/01/2018 - 13:01

As More Physicians Seek Non-Opioid Treatment Options, the Vectors Study Will Further Advance Understanding of New Approaches to Optimal Spinal Cord Stimulation Treatment DUBLIN - January 9, 2018 - Medtronic plc (NYSE: [...]

Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer

09/01/2018 - 13:00

NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP ) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, [...]

Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018

09/01/2018 - 13:00

BERKELEY HEIGHTS, N.J., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC ) (Nasdaq: CYCCP ) (Cyclacel or the Company) reviewed its 2017 achievements and provided an outline of the Company's [...]

Summit Therapeutics to Present at the Biotech Showcase

09/01/2018 - 13:00

OXFORD, United Kingdom, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, [...]

Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference

09/01/2018 - 13:00

- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO ® (nivolumab) - - Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology [...]

IRIDEX Announces Infringement Lawsuit Against Quantel

09/01/2018 - 13:00

MOUNTAIN VIEW, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX ) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. in the U.S. [...]

Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial

09/01/2018 - 13:00

COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone resorption confirms [...]

CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study

09/01/2018 - 13:00

BASEL, Switzerland, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON ) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously reported in its [...]

FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study

09/01/2018 - 13:00

Program Allows for Collection of Real-World Data Alongside the Company’s Ongoing Phase III Study in CLI FDA May Also Allow Pluristem to Be Compensated for the Cost of Treatment HAIFA, Israel, Jan. 09, 2018 (GLOBE [...]

Transactions in relation to share buyback program

09/01/2018 - 11:50

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Genetic Technologies Regains Nasdaq Listing Compliance

09/01/2018 - 11:00

MELBOURNE, Australia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq: GENE ) (“Company”), is pleased to advise that the Company received a notification letter (the "Notice") from the [...]

Veritas Pharma Provides Comment on U.S. Attorney General Jeff Sessions Memo

09/01/2018 - 09:05

VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) and (Frankfurt: 2VP ) , (“Veritas” or the “Company”) provides the following statement to the memorandum issued by [...]

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

09/01/2018 - 07:16

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial versus Humira ® * in psoriatic arthritis ( [...]

Cannabis Wheaton Income Corp. Announces Strategic Investment and Alliance With Inner Spirit Holdings Ltd.

09/01/2018 - 06:57

VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX-V: CBW ) (" Wheaton Income " or the " Company ") is pleased to announce that it has entered into [...]

Breathtec Biomedical Unaware of Any Material Change

09/01/2018 - 04:43

VANCOUVER, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical, Inc. (CSE:BTH) (OTCQB:BTHCF) (the “ Company ” or “ Breathtec ”) - at the request of the Investment Industry Regulatory Organization of [...]

Quotient Limited Reports Further Positive Data on its Initial Disease Screening Microarray and Provides Update on Blood Grouping

09/01/2018 - 02:15

Performance evaluation studies for the initial disease screening microarray demonstrate 100% sensitivity and >99% specificity for the CMV and Syphilis assays V&V for blood grouping is ongoing – pending a [...]